Heart Disease and Relaxin: New Actions for an Old Hormone,Trends in Endocrinology & Metabolism

当前位置： X-MOL 学术 › Trends Endocrin. Met. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Heart Disease and Relaxin: New Actions for an Old Hormone
Trends in Endocrinology & Metabolism ( IF 11.4 ) Pub Date : 2018-05-01 , DOI: 10.1016/j.tem.2018.02.008
Teja Devarakonda ₁ , Fadi N Salloum ₁

Affiliation

The hormone relaxin has long been recognized for its involvement in maternal adaptation during pregnancy. However, discoveries during the past two decades on the mechanism of action of relaxin, its family of receptors, and newly described roles in attenuating ischemia/reperfusion (I/R) injury, inflammation, and arrhythmias have prompted vast interest in exploring its therapeutic potential in cardiovascular disease. These observations inspired recently concluded clinical trials in patients with acute heart failure. This review discusses our current understanding of the protective signaling pathways elicited by relaxin in the heart, and highlights important new breakthroughs about relaxin signaling that may pave the way to more carefully designed future trials.

中文翻译：

心脏病和松弛素：古老激素的新作用

人们早已认识到松弛素激素与怀孕期间的母亲适应有关。然而，过去二十年对松弛素及其受体家族作用机制的发现，以及新描述的在减轻缺血/再灌注 (I/R) 损伤、炎症和心律失常中的作用，引起了人们对探索其治疗潜力的巨大兴趣在心血管疾病中。这些观察结果启发了最近完成的针对急性心力衰竭患者的临床试验。这篇综述讨论了我们目前对心脏中松弛素引起的保护性信号通路的理解，并强调了松弛素信号传导方面的重要新突破，这可能为未来更精心设计的试验铺平道路。

更新日期：2018-05-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文